R. Grimée

524 total citations
30 papers, 440 citations indexed

About

R. Grimée is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Spectroscopy. According to data from OpenAlex, R. Grimée has authored 30 papers receiving a total of 440 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Cellular and Molecular Neuroscience and 6 papers in Spectroscopy. Recurrent topics in R. Grimée's work include Neuroscience and Neuropharmacology Research (5 papers), Neurological disorders and treatments (4 papers) and Parkinson's Disease Mechanisms and Treatments (4 papers). R. Grimée is often cited by papers focused on Neuroscience and Neuropharmacology Research (5 papers), Neurological disorders and treatments (4 papers) and Parkinson's Disease Mechanisms and Treatments (4 papers). R. Grimée collaborates with scholars based in Belgium, France and United Kingdom. R. Grimée's co-authors include Henrik Klitgaard, Alan R. Crossman, Erwan Bézard, Jonathan M. Brotchie, Michael P. Hill, Anne Michel, R. Mathur-De Vré, D. Mărgineanu, Alain Matagne and Ernst Wülfert and has published in prestigious journals such as Journal of Pharmacology and Experimental Therapeutics, Magnetic Resonance in Medicine and Life Sciences.

In The Last Decade

R. Grimée

30 papers receiving 428 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. Grimée Belgium 11 212 174 84 70 49 30 440
Aquilonius Sm Sweden 9 265 1.3× 301 1.7× 147 1.8× 46 0.7× 45 0.9× 20 622
Mitchell S. Gandelman United States 10 183 0.9× 76 0.4× 137 1.6× 63 0.9× 32 0.7× 12 543
G Dordain France 16 218 1.0× 265 1.5× 112 1.3× 117 1.7× 38 0.8× 56 670
Ann C. McKeon United States 10 265 1.3× 63 0.4× 146 1.7× 100 1.4× 37 0.8× 11 379
M.J. Adam Canada 14 210 1.0× 218 1.3× 150 1.8× 70 1.0× 47 1.0× 36 787
Victor Garza United States 16 285 1.3× 104 0.6× 251 3.0× 55 0.8× 53 1.1× 20 602
SA Eckernas Sweden 7 159 0.8× 116 0.7× 59 0.7× 21 0.3× 23 0.5× 8 375
Bengt Långström Sweden 12 159 0.8× 48 0.3× 123 1.5× 93 1.3× 43 0.9× 17 485
Jay J. Rubin United States 8 135 0.6× 112 0.6× 112 1.3× 93 1.3× 12 0.2× 9 455
I. Gottfries Sweden 7 177 0.8× 115 0.7× 64 0.8× 110 1.6× 38 0.8× 10 483

Countries citing papers authored by R. Grimée

Since Specialization
Citations

This map shows the geographic impact of R. Grimée's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Grimée with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Grimée more than expected).

Fields of papers citing papers by R. Grimée

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Grimée. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Grimée. The network helps show where R. Grimée may publish in the future.

Co-authorship network of co-authors of R. Grimée

This figure shows the co-authorship network connecting the top 25 collaborators of R. Grimée. A scholar is included among the top collaborators of R. Grimée based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Grimée. R. Grimée is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fuks, B. B., et al.. (2005). In vitro properties of 5-(benzylsulfonyl)-4-bromo-2-methyl-3(2H)-pyridazinone: A novel permeability transition pore inhibitor. European Journal of Pharmacology. 519(1-2). 24–30. 15 indexed citations
2.
Hill, Michael P., Jonathan M. Brotchie, Alan R. Crossman, et al.. (2004). Levetiracetam Interferes With the l-Dopa Priming Process in MPTP-Lesioned Drug-Naive Marmosets. Clinical Neuropharmacology. 27(4). 171–177. 21 indexed citations
3.
Hill, Michael P., Paula Ravenscroft, Erwan Bézard, et al.. (2004). Levetiracetam Potentiates the Antidyskinetic Action of Amantadine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson’s Disease. Journal of Pharmacology and Experimental Therapeutics. 310(1). 386–394. 66 indexed citations
4.
Bézard, Erwan, Michael P. Hill, Alan R. Crossman, et al.. (2004). Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. European Journal of Pharmacology. 485(1-3). 159–164. 58 indexed citations
5.
Brotchie, Jonathan M., Anne Michel, Erwan Bézard, et al.. (2003). Levetiracetam (keppra) potentiates the anti-dyskinetic action of amantadine in the MPTP-lesioned marmoset model of Parkinson's disease. Journal of Pharmacology and Experimental Therapeutics. 1 indexed citations
6.
Hill, Michael P., Erwan Bézard, Alan R. Crossman, et al.. (2003). Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L‐dopa and ropinirole in the MPTP‐lesioned marmoset. Movement Disorders. 18(11). 1301–1305. 43 indexed citations
7.
8.
Ryckmans, Thomas, Olivier Berton, R. Grimée, et al.. (2003). Dual NK1 Antagonists—Serotonin Reuptake Inhibitors as Potential Antidepressants. Part 2. SAR and Activity of Benzyloxyphenethyl Piperazine Derivatives.. ChemInform. 34(8). 1 indexed citations
9.
Grimée, R., et al.. (2003). P.1.162 The antiepileptic drug levetiracetam modulates plasma corticosterone levels in two rat models of HPA axis activation. European Neuropsychopharmacology. 13. S243–S243. 1 indexed citations
10.
Ryckmans, Thomas, Olivier Berton, R. Grimée, et al.. (2002). Dual NK1 antagonists—serotonin reuptake inhibitors as potential antidepressants. Part 2: SAR and activity of benzyloxyphenethyl piperazine derivatives. Bioorganic & Medicinal Chemistry Letters. 12(21). 3195–3198. 28 indexed citations
11.
Bocquet, Arnaud, et al.. (2001). Failure of GPI compounds to display neurotrophic activity in vitro and in vivo. European Journal of Pharmacology. 415(2-3). 173–180. 22 indexed citations
12.
Grimée, R. & Ernst Wülfert. (1995). Acute stress in rats produces a rapid and sustained increase in prostacyclin production in aortic tissue: Dependence on corticosterone. Life Sciences. 57(1). 69–81. 10 indexed citations
13.
Grimée, R., et al.. (1988). Formation and degradation of 1-(ethyl)-1-(2-hydroxyethyl) aziridinium chloride in aqueous media—a comparative NMR study. Journal of Neuroscience Methods. 23(2). 101–105. 11 indexed citations
14.
Grimée, R., et al.. (1985). [Toxicity of sneezing powders. I. Study of prohibited constituents in sneezing powders].. PubMed. 39(6). 371–9. 2 indexed citations
15.
Vré, R. Mathur-De, et al.. (1985). The use of agar gel as a basic reference material for calibrating relaxation times and imaging parameters. Magnetic Resonance in Medicine. 2(2). 176–179. 45 indexed citations
16.
Grimée, R., et al.. (1984). In vitro metabolism of procyclidine in the rat. European Journal of Drug Metabolism and Pharmacokinetics. 9(4). 311–313. 2 indexed citations
17.
Gelbcke, Michel, et al.. (1983). Spectres RMN‐1H et ‐13C de L'Acide Mercapto‐6 Pyridinecarboxylique‐2 et de Ses Dérivés Méthyles Correspondants. Bulletin des Sociétés Chimiques Belges. 92(5). 459–463. 4 indexed citations
18.
Vré, R. Mathur-De, et al.. (1983). Experimental protocol for tissue discrimination in vitro by n.m.r.. Bioscience Reports. 3(7). 599–608. 6 indexed citations
19.
Gelbcke, Michel, et al.. (1982). Étude en RMN du Carbone‐13 de Quelques Colorants (Quinoleinyl‐2′)‐2 Indanedione‐1, 3 Sulfones. Bulletin des Sociétés Chimiques Belges. 91(3). 237–242. 2 indexed citations
20.
Tourwé, Dirk, et al.. (1980). 1-(3-Hydroxycyclohexyl)-1-phenyl-3-(1-pyrrolidinyl)-1-propanol, a procyclidine metabolite.. Drug Metabolism and Disposition. 8(2). 115–116. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aquilonius Sm Breakdown of academic impact, for papers by Mitchell S. Gandelman Breakdown of academic impact, for papers by G Dordain Breakdown of academic impact, for papers by Ann C. McKeon Breakdown of academic impact, for papers by M.J. Adam Breakdown of academic impact, for papers by Victor Garza Breakdown of academic impact, for papers by SA Eckernas Breakdown of academic impact, for papers by Bengt Långström Breakdown of academic impact, for papers by Jay J. Rubin Breakdown of academic impact, for papers by I. Gottfries
Rankless by CCL
2026